

Bevacizumab E2100

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS


Quality of life



Serious and disabling adverse effects



Other adjustments



Bevacizumab E2100

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: First-line treatment of adult patients with metastatic breast cancer  
Experimental Arm: Bevacizumab + Paclitaxel  
Control Arm: Paclitaxel

